Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02698891 · ClinicalTrials.gov registry record · Phase 2
Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer
A Phase 2 study of Early Stage Breast Cancer, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 127
- Enrollment target
- 4
- Study locations
NCT02698891 is a Phase 2 study of Early Stage Breast Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 127 participants, below the 408-participant average among 21 other Early Stage Breast Cancer trials with a reported enrollment target (69% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT02698891, a Phase 2 study of Early Stage Breast Cancer, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 127 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research study is testing the safety and feasibility of delivering the 4 cycles of 'dose-dense' paclitaxel without the use of Neulasta (Pegfilgrastim) as a Granulocyte Colony-stimulating Factor (G-CSF) support. The research study is for participants who have early stage breast cancer and have been recommended to receive a standard chemotherapy regimen, doxorubicin/cyclophosphamide (AC) plus Paclitaxel (T), in what is called a "dose-dense" fashion to prevent recurrences.
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG Neulasta
Study Locations (4)
Massachusetts
- Dana-Farber Cancer Institute - Boston
- Dana-Farber at Milford Regional Cancer Center - Milford
- Dana-Farber Cancer Institute at South Shore - Weymouth
New Hampshire
- Dana-Farber/New Hampshire Oncology-Hematology - Londonderry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2016-04-07 |
| Est. Completion | 2021-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02698891
The ClinicalTrials.gov registry entry for NCT02698891 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 408-participant average among 21 other Early Stage Breast Cancer trials with a reported enrollment target (69% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Early Stage Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Paclitaxel is the first listed.
NCT02698891 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New Hampshire.
Frequently Asked Questions
What is clinical trial NCT02698891 about?
NCT02698891 is a clinical study titled "Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer". This research study is testing the safety and feasibility of delivering the 4 cycles of 'dose-dense' paclitaxel without the use of Neulasta (Pegfilgrastim) as a Granulocyte Colony-stimulating Factor (G-CSF) support. The research study is for participants who have early stage breast cancer and have b...
What is the current status of trial NCT02698891?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 127 participants. The study started on 2016-04-07. Estimated completion is 2021-11.
What conditions does trial NCT02698891 study?
This clinical trial studies the following conditions: Early Stage Breast Cancer.
What interventions are being tested in trial NCT02698891?
The interventions under investigation include: Paclitaxel (DRUG), Neulasta (DRUG).
Who is sponsoring clinical trial NCT02698891?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02698891 being conducted?
This trial has 4 study locations across Massachusetts, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Early Stage Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients
RECRUITING · Phase 2
-
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RECRUITING · Phase 2
-
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
RECRUITING · Phase 2
-
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
RECRUITING · Phase 2
-
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
RECRUITING · Phase 2
-
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.